MilliporeSigma Recognized with CPhI Awards for Innovative Products
- Company awarded for excellence in innovation for Parteck® MXP Excipient and modified amino acids
Burlington, Massachusetts, October 12, 2018 – MilliporeSigma today announced that it has won two CPhI Pharma Awards for innovative products for the pharmaceutical industry. The awards were announced at CPhI’s award gala in Madrid, Spain. CPhI (Convention on Pharmaceutical Ingredients) Pharma is a global organization that connects people within the pharmaceutical industry and celebrates thinkers, creators and companies breaking new ground.
“At MilliporeSigma, we provide innovations that help our customers advance science and accelerate access to better health for people everywhere,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “We are pleased that CPhI has recognized our commitment to drive the industry forward and empower researchers and scientists with products that improve drug development quality and efficiency.”
The company received the following awards:
Parteck® MXP Excipient won for “Excellence in Excipients.” Parteck® MXP excipient is a new polyvinyl alcohol excipient for the formulation of stable amorphous solid dispersions by hot melt extrusion, providing enhanced solubility of active pharmaceutical ingredients (APIs) and stable, high drug loads. The new excipient is applicable for a variety of final formulations with different release kinetics and offers the formulator flexibility in designing a drug product that fits the respective API and desired therapeutic effect.
MilliporeSigma’s modified amino acids won for “Excellence in Bioprocessing and Manufacturing.” The modified amino acids Phospho-Tyrosine disodium salt and Sulfo-Cysteine sodium salt are components for biomanufacturing and mAb processes, designed to simplify fed batch processes in applying a single-feed strategy.
CPhI Pharma is a global organization that connects people within the pharmaceutical sector and creates opportunities for pharma companies to develop new business, meet customers, launch new products, promote brands and expand into new markets. The CPhI Pharma Awards celebrate thinkers and creators breaking new ground in the industry and advocate companies that are committed to driving the industry forward.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15.3 billion in 2017. Around 53,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany, continued its growth trajectory in the second quarter of 2022 despite a challenging environment. Net sales increased by 14.3% compared with the second quarter of 2021 to ...